0 108

Cited 0 times in

Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter-2 inhibitor, with phentermine in healthy subjects

Authors
 Sukyong Yoon  ;  Min Soo Park  ;  Byung Hak Jin  ;  Hyobin Shin  ;  Jaejin Na  ;  Wan Huh  ;  Choon Ok Kim 
Citation
 Expert Opinion on Drug Metabolism & Toxicology, Vol.19(7) : 479-485, 2023-08 
Journal Title
Expert Opinion on Drug Metabolism & Toxicology
Issue Date
2023-08
MeSH
Adult ; Area Under Curve ; Cross-Over Studies ; Drug Interactions ; Glucose ; Healthy Volunteers ; Humans ; Phentermine / adverse effects ; Sodium ; Sodium-Glucose Transporter 2 Inhibitors* / pharmacology ; Weight Loss
Keywords
DWP16001 ; Drug interaction ; pharmacodynamics ; pharmacokinetics ; phentermine
Abstract
Background: DWP16001, a sodium-glucose cotransporter-2 inhibitor, has shown promise for improving blood glucose control and facilitating weight loss. Co-administration with phentermine could enhance these effects. So, we aimed to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) interactions of DWP16001 and phentermine.

Methods: We conducted a randomized, open-label, 3-treatment, 6-sequence, 3-period crossover study involving 24 healthy adults. Participants received either DWP16001 (2 mg), phentermine (37.5 mg), or a combination of both once daily for 7 days. Blood samples, urine samples, and body weights were collected to evaluate the PK and PD.

Results: The PK of the combination was found to be similar to that of the monotherapy. The geometric mean ratio (GMR) of Cmax,ss, and AUCtau,ss were 0.98 and 1.00, respectively, for DWP16001, and 1.01 and 0.94, respectively, for phentermine. Co-administration did not significantly affect the 24-hour urinary glucose excretion compared to DWP16001 monotherapy, and the GMR was 0.90. Participants tended to experience greater weight loss in the combination therapy group, and all demonstrated good tolerance.

Conclusions: Our findings indicate that there were no significant interactions during co-administration. These results suggest that the combination of DWP16001 and phentermine may be safe and effective for the treatment of obesity and diabetes.
Full Text
https://www.tandfonline.com/doi/full/10.1080/17425255.2023.2249397
DOI
10.1080/17425255.2023.2249397
Appears in Collections:
6. Others (기타) > Dept. of Clinical Pharmacology (임상시험센터) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Choon Ok(김춘옥) ORCID logo https://orcid.org/0000-0002-2319-1108
Park, Min Soo(박민수) ORCID logo https://orcid.org/0000-0002-4395-9938
Yoon, Sukyong(윤석용)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/196776
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links